![]() |
Volumn 136, Issue 10, 2017, Pages 969-972
|
Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease
|
Author keywords
Branched chain amino acids; Cardiovascular disease; Empagliflozin; Ketone bodies; Metabolomics; SGTL2 inhibitors; Type 2 diabetes mellitus
|
Indexed keywords
BRANCHED CHAIN AMINO ACID;
EMPAGLIFLOZIN;
GLUCAGON;
GLUCOSE;
ISOLEUCINE;
KETONE BODY;
LEUCINE;
VALINE;
BENZHYDRYL DERIVATIVE;
BIOLOGICAL MARKER;
GLUCOSIDE;
ADULT;
CARDIOVASCULAR DISEASE;
CATABOLISM;
CITRIC ACID CYCLE;
CLINICAL ARTICLE;
FEMALE;
HUMAN;
LETTER;
MALE;
METABOLOMICS;
NON INSULIN DEPENDENT DIABETES MELLITUS;
PRIORITY JOURNAL;
AGED;
BLOOD;
CARDIAC MUSCLE;
DRUG EFFECT;
ENERGY METABOLISM;
METABOLISM;
MIDDLE AGED;
PROCEDURES;
PROSPECTIVE STUDY;
TREATMENT OUTCOME;
AGED;
BENZHYDRYL COMPOUNDS;
BIOMARKERS;
CARDIOVASCULAR DISEASES;
DIABETES MELLITUS, TYPE 2;
ENERGY METABOLISM;
FEMALE;
GLUCOSIDES;
HUMANS;
MALE;
METABOLOMICS;
MIDDLE AGED;
MYOCARDIUM;
PROSPECTIVE STUDIES;
SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;
TREATMENT OUTCOME;
|
EID: 85031040731
PISSN: 00097322
EISSN: 15244539
Source Type: Journal
DOI: 10.1161/CIRCULATIONAHA.117.029166 Document Type: Letter |
Times cited : (123)
|
References (5)
|